Celldex Therapeutics
CLDX

$43.76

1.22%

Market Cap: $2.9B

About: Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Employees: 160

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

65% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 49

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

2.58% less ownership

Funds ownership: 108.17% [Q1] → 105.59% (-2.58%) [Q2]

9% less funds holding

Funds holding: 196 [Q1] → 179 (-17) [Q2]

12% less capital invested

Capital invested by funds: $2.92B [Q1] → $2.58B (-$349M) [Q2]

44% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 39

80% less call options, than puts

Call options by funds: $3.39M | Put options by funds: $17M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$37

15%

downside

Avg. target

$69

57%

upside

High target

$80

83%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Wells Fargo Derek Archila 53% 1-year accuracy 16 / 30 met price target	15%downside $37	Equal-Weight Maintained	12 Aug 2024
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target	83%upside $80	Buy Reiterated	12 Aug 2024
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target	53%upside $67	Overweight Reiterated	30 Jul 2024
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target	83%upside $80	Buy Reiterated	30 Jul 2024
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target	83%upside $80	Buy Reiterated	16 Jul 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago.

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update.

Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD.

Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients -

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU -

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024

Zacks Investment Research

Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet

The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. Mast cells are believed to play an important role in amplifying chronic itch and neuroinflammation, including in PN where mast cells are associated with pruritic sensory neurons in PN lesions.

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Celldex Therapeutics: Rising High, With Room For Further Growth

Celldex Therapeutics is a biopharmaceutical company with a strong pipeline of potential treatments. The company has a solid financial outlook, which is a positive factor for investors. If you respect the risks of investing based on phase 2 data, CLDX has a lot of promise yet unrealized.

Celldex Therapeutics: Rising High, With Room For Further Growth

Zacks Investment Research

Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade

The consensus price target hints at a 67.8% upside potential for Celldex (CLDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade

See News Rankings